telmisartan / Generic mfg. - LARVOL DELTA

Cardioprotection without risk? meta-analysis of prophylactic agents in low-risk cancer patients on anthracyclines (ASH 2025) - "We included randomized controlled trials (RCTs) of prophylactic ACE inhibitors, ARBs, beta-blockers, statins, dexrazoxane, or SGLT2 inhibitors in adults without pre-existing cardiovascular risk factors...Agents studied included beta-blockers (nebivolol, carvedilol, bisoprolol), ACE inhibitors (ramipril), ARBs (telmisartan), and spironolactone. Treatment duration ranged from 4 months to 1 year; anthracycline doses reached up to 689 mg/m² (epirubicin) or 536 mg/m² (doxorubicin)...The protective benefit was greater in contexts involving higher cumulative anthracycline doses and concurrent cardiotoxic therapies such as trastuzumab...However, high heterogeneity limits firm conclusions. Given the moderate effect size and heterogeneity, further large-scale, well-formulated trials are essential to identify optimal cardioprotective agents and precise patient selection criteria."

Retrospective data • Breast Cancer • Congestive Heart Failure • Heart Failure • Oncology • Solid Tumor

Decoding the Neuroprotective Intervention of Angiotensin Receptor Blockers: A Multimodal Approach Using In Silico Network Pharmacology, Molecular Modeling, and In Vivo Validation of Key Markers. (PubMed, ACS Chem Neurosci) - "Building on these findings, this study sought to compare the activity of azilsartan with other commonly used ARBs, including telmisartan, olmesartan, valsartan, eprosartan, irbesartan, and candesartan, using an integrative network pharmacology approach. To experimentally validate these predictions, in vivo studies were conducted in a scopolamine-induced memory-impaired model, which demonstrated significant restoration of the levels of AKT1 and PIK3CA. These findings clearly demonstrate the PI3K/AKT modulating effects of azilsartan, reinforcing its repurposing potential in dementia and related disorders, thereby expanding novel therapeutic opportunities within this drug class."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • AKT1 • PIK3CA • PIK3CB

Efficacy and Safety of HB-1 for Panic Disorder (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: Honeybrains Biotech LLC | Trial completion date: Feb 2026 ➔ Feb 2027 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Psychiatry

Greenness Assessment of HPLC-UV Method for Simultaneous Estimation of Four Antihypertensive Drugs. (PubMed, J Chromatogr Sci) - "An environmentally friendly HPLC method was developed to estimate angiotensin receptor blocker (telmisartan) and calcium channel blockers (cilnidipine, benidipine and azelnidipine) in a single run. To assess the environmental impact of the method, five greenness evaluation criteria, namely, the Green Analytical Procedure Index, Analytical GREEness, Chlortox Scale, Blue Applicability Grade Index, and Red-Blue-Green 12, were adopted. Concerning all the tools, the proposed method was found to be green."

Journal

Pharmacogenomics-Guided Precision Therapy for Chronic Kidney Disease with Resistant Hypertension: A Prospective Cohort Study. (PubMed, Kidney Blood Press Res) - "PGx-guided precision therapy facilitates rapid BP control, reduces polypharmacy and adverse events, and delays kidney function decline in CKD patients with RH. This study, the first PGx clinical trial targeting a multi-ethnic population in Northwest China, offers valuable insights into personalized treatment approaches for CKD with RH in East Asia."

Biomarker • Journal • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

Validated LC-MS/MS Method for the Quantitative Determination and Pharmacokinetic Profiling of Fedratinib (TG101348), an Oral JAK2 Inhibitor, in CD1 Mice Plasma. (PubMed, Biomed Chromatogr) - "Telmisartan was used as the internal standard (IS). Stability studies confirmed the analyte's integrity across multiple freeze-thaw cycles. The developed LC-MS/MS method is selective, sensitive, fully validated, and was successfully applied to pharmacokinetic studies."

Journal • PK/PD data • Preclinical • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • JAK2

Attenuation of cerebral ischemia-reperfusion induced neurotoxicity by telmisartan, ertugliflozin, and omaveloxolone through Nrf2/HO-1 pathway modulation: In vivo and in silico insights. (PubMed, Toxicol Rep) - "In silico analysis revealed strong binding through highly negative docking scores of telmisartan and ertugliflozin to Nrf2 negative regulators Keap1 and GSK-3β, supported by stable molecular dynamics simulations, suggesting direct inhibition. In conclusion, omaveloxolone, telmisartan, and ertugliflozin alleviate ischemia-reperfusion induced neurotoxicity via potential Nrf2-mediated antioxidant and anti-inflammatory mechanisms, highlighting their potential preventive role in conditions predisposing to stroke."

Journal • Preclinical • Cardiovascular • CNS Disorders • Diabetes • Hypertension • Metabolic Disorders • Oncology • Reperfusion Injury • Vascular Neurology • HMOX1 • IL6 • KEAP1 • MMP9 • TNFA

Telmisartan reduces systemic inflammation and alters the renin-angiotensin system in mild COVID-19. (PubMed, Sci Rep) - "Taken collectively, these results show TEM mediated activation of the Ang(1-7)/MasR/ACE2 pro-resolving arm of RAS, which activates anti-inflammatory events that reduce global inflammation. These findings support the use of ARBs like TEM in mitigating COVID-19 driven alterations in RAS."

Clinical • Journal • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • ANGPT1

A novel in vivo phenotypic assay to evaluate kinase inhibitor induced cardiotoxicity and strategies for cardioprotection. (PubMed, Food Chem Toxicol) - "Heart function was rescued by discontinuation of treatment with axitinib and ponatinib but not with the sorafenib. Co-treatment with ramipril or telmisartan reduced the extent of sorafenib-induced heart failure. Thus, the embryos of L. stagnalis serve as a valuable invertebrate model of cardiotoxicity not just for the high-throughput pre-clinical phenotypic screening of chemotherapeutics but also for testing of harmful chemicals and environmental pollutants. Further, this novel model is amenable for the testing of cardioprotection strategies such as treatment discontinuation as well as the identification of additional treatment options that can be combined with cancer therapeutics to prevent cardiotoxicity."

Journal • Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Oncology

Clinical pharmacokinetics on canagliflozin: a systematic review of in-vitro and in-vivo studies. (PubMed, Expert Rev Clin Pharmacol) - "Furthermore, co-administration of CFZ with rifampin in humans reduced Cmax by 28%, while with telmisartan in rats, CL/F decreased 31.1% initially, but increased 62.9% after 7 days. This review integrates all significant human PK parameters of CFZ by combining findings from existing studies, allowing researchers to develop and evaluate PK models for recommending model-based dose optimization. : CRD420251054714."

Journal • PK/PD data • Preclinical • Review • Diabetes • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus

Clinical practices in feline chronic kidney disease: A cross-sectional study of primary care veterinarians in Turkey. (PubMed, Acta Vet Hung) - "Telmisartan and ACE inhibitors were commonly used, but amlodipine was prescribed by only 8.9%...Although awareness of international guidelines is high, discrepancies remain in disease substaging, blood pressure monitoring and antihypertensive drug selection. Greater emphasis on blood pressure measurement and improved access to feline-licensed drugs may enhance CKD management in cats."

Journal • Observational data • Nephrology • Renal Disease

Effects of Inhibitors of the Activity of the Circulating Renin-Angiotensin System on the Growth and Proliferation of Endometrial Cancer Cells. (PubMed, Int J Mol Sci) - "We then determined the effects of drugs that inhibit the action of renin (VTP-27999 and aliskiren) or angiotensin-converting enzyme (perindoprilat) or block the angiotensin II type 1 receptor (losartan and telmisartan). RAS inhibitors were most effective in Ishikawa cells, which had the highest levels of RAS expression. Therefore, levels of RAS expression in endometrial cancers might indicate the potential efficacy of RAS drugs."

Journal • Endometrial Cancer • Oncology • Solid Tumor

Dual-Targeted Therapy in Cardiometabolic Risk: A Meta-Analysis of Telmisartan-Based Combinations for Hypertension and Dyslipidemia. (PubMed, Clin Cardiol) - "Telmisartan + amlodipine demonstrates superior antihypertensive efficacy, while telmisartan + rosuvastatin more effectively lowers LDL-C. Safety profiles are comparable. Findings support the selection of a regimen based on individualized therapeutic goals."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

TRÍADE-HA: A Study to Investigate Efficacy and Safety of a TCA108 in Participants ≥18 Years With Uncontrolled Hypertension (clinicaltrials.gov) - P3 | N=400 | Not yet recruiting | Sponsor: EMS | N=282 ➔ 400 | Initiation date: Mar 2026 ➔ Nov 2026

Enrollment change • Trial initiation date • Cardiovascular • Hypertension

Pharmacological and bioinformatics analysis reveals the reno-protective mechanisms of Zhenwu Decoction in chronic kidney disease. (PubMed, Comput Biol Chem) - "Our present study shows the potential of Zhenwu Decoction in the management of chronic kidney disease using a bioinformatics and network pharmacology strategy to target kidney function and programmed cell death. Its active components advanced our knowledge of TCM's multi-target effects by improving kidney health in a rat model of doxorubicin-induced nephropathy."

Journal • Chronic Kidney Disease • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease • mTOR • PARP2 • TGFB1 • TIMP3

Telmisartan targets Nrf2-HO1 axis in MASLD modulating oxidative stress, inflammation, and mitochondrial dysfunction: mechanistic insights. (PubMed, Libyan J Med) - "MASLD induced marked hepatic fibrosis, which was markedly improved following TEL treatment. TEL has notable hepatoprotective properties in MASLD by enhancing metabolic parameters, decreasing oxidative stress, and moderating inflammatory reactions."

Journal • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • CAT • IL6 • MMP9 • TGFB1 • TIMP1 • TNFA

Lowering melt extrusion temperature and increasing solubility and dissolution rate of telmisartan amorphous solid dispersion by applying acid-base supersolubilization principle. (PubMed, Int J Pharm) - "DSC and PXRD of extrudates confirmed complete conversion of telmisartan to the amorphous state, which dissolved much faster than crystalline telmisartan. Thus, the ABS approach provided a rapidly dissolving ASD of telmisartan that could be extruded at the relatively low temperature of 120 °C."

Journal

Conservation in the Andean Highlands of South America: A Habitat Enhancement Plan for Tematobius philippii, a Critically Endangered Species in the Ascotán Salt Flat in Chile. (PubMed, Animals (Basel)) - "This demonstrates the positive effect of artificial refuges as a practical tool for the recovery of Telmatobius populations. To our knowledge, this study provides the first documented case of successful habitat enhancement for this threatened group of high Andean amphibians, offering a replicable strategy for conservation in fragile ecosystems."

Journal

Dapagliflozin: Ally or Risk? (KIDNEY WEEK 2025) - "Treatment was initiated with telmisartan, furosemide, and methylprednisolone boluses. Although dapagliflozin offers nephroprotective benefits, its initiation should be delayed until clinical stabilization in patients with nephrotic syndrome. Additionally, the concurrent use of diuretics should be considered carefully, as it may increase the risk of developing acute kidney injury."

Acute Kidney Injury • Chronic Kidney Disease • Fatigue • Glomerulonephritis • Nephrology • Renal Disease

Resistant Hypertension in ANCA-Associated Vasculitis: Role for Aliskiren? (KIDNEY WEEK 2025) - "Despite receiving cyclophosphamide and methylprednisolone, he remained dialysis-dependent and was referred for renal transplant. He had multiple hypertensive emergency admissions despite a multi-drug regimen with nifedipine, telmisartan, carvedilol, eplerenone, clonidine, and hydralazine, and dry weight optimization...Studies are warranted to compare DRI efficacy against standard antihypertensives in similar clinical scenarios. The views expressed in this abstract are those of the author(s) and do not necessarily reflect the official policy of the Department of Defense or the U.S. Government."

ANCA Vasculitis • Cardiovascular • Glomerulonephritis • Hypertension • Inflammation • Lupus Nephritis • Nephrology • Renal Disease • Vasculitis • MPO

Primary or Secondary? A Diagnostic Dilemma in Tip Lesion FSGS (KIDNEY WEEK 2025) - "Diclofenac tablets were discontinued, and she was managed conservatively with telmisartan, bumetanide, and dietary sodium restriction. Although the biopsy showed features typical of primary FSGS (tip lesion and diffuse podocyte effacement), the clinical context pointed to a secondary NSAID-induced cause. Moving forward, a more precise classification system is needed to better distinguish subtypes as this is crucial in guiding appropriate management."

Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • Pulmonary Disease • Renal Disease

Gitelman-Like Syndrome Secondary to Occupational Solvent Inhalation (KIDNEY WEEK 2025) - "Following a period of treatment, the patient was discharged on a medication regimen consisting of telmisartan, spironolactone, potassium, magnesium sulfate, and aspirin. Treatment focused on correcting fluid and electrolyte imbalances, with potassium normalized over 10 days and supplements given. Though genetic testing and renin levels couldn't be measured, the findings indicated a Gitelman-like syndrome caused by solvent inhalation."

Cardiovascular • Endocrine Disorders • Fatigue • Hematological Disorders • Hypertension • Hypotension • Immunology • Metabolic Disorders • Thrombocytosis • SLC2A3

Dual antihypertensive strategies: A real-world comparative study of efficacy and safety of fixed-dose combinations in a tertiary care setting. (PubMed, Perspect Clin Res) - "The aim of this study was to evaluate the comparative efficacy and safety of fixed-dose combinations of amlodipine 5 mg + hydrochlorothiazide 12.5 mg (A+H) (Group 1), telmisartan 40 mg + hydrochlorothiazide 12.5 mg (T+H) (Group 2), and ramipril 5 mg + hydrochlorothiazide 12.5 mg (R+H) (Group 3) in patients of essential hypertension...Adverse drug reactions (ADRs) were highest in the A+H group at 29.4% and lowest in the T+H group at 19.8%. This real-world clinical study provided valuable insights into the comparative efficacy of different antihypertensive drug combinations, with T+H being most effective in reducing SBP; in terms of DBP, all the groups were equally efficacious."

Journal • Real-world evidence • Cardiovascular • Hypertension

4-Octyl Itaconate Promotes Diabetic Wound Healing by Enhancing Pro-Resolving Macrophages via the Efferocytosis-MCT1-Lactate-GPR132 Pathway and Macrophage-Independent Synergistic Effects. (PubMed, Diabetes Metab J) - "To further evaluate the roles of macrophages, monocarboxylate transporter 1 (MCT1), and lactate in 4-OI-promoted diabetic wound healing, we used clodronate-liposomes (CLD-Lipo) to deplete macrophages, AZD3965 (an MCT1 inhibitors), telmisartan to validate our hypothesis. 4-OI promotes diabetic wound healing through macrophage-dependent/independent mechanisms. Moreover, the protective effect of 4-OI on macrophage was mediated through MCT1-mediated lactate release triggered by efferocytosis and subsequent GRP132 activation."

Journal • Diabetes • Metabolic Disorders • GPR132 • SLC16A1

A novel deep learning framework identified associated genes and Interpretable deep learning translation of GWAS findings for drug repurposing in Atrial Fibrillation (AHA 2025) - "Using a novel deep learning methodology that utilized GWAS and QTL findings, we identified risk genes and repurposing drug candidates for AF."

Atrial Fibrillation • Cardiovascular • CAV1